INTRODUCTION
============

With advances in medical treatment for acute disease, chronic non-communicable diseases are now the major cause of morbidity and mortality in both developing and developed countries \[[@R1]\]. One typical example of non-communicable disease is peripheral artery disease (PAD), the third leading cause of atherosclerotic morbidity, after coronary artery disease (CAD) and stroke \[[@R2]\]. The prevalence of PAD increases with age, affecting 6% of individuals aged 50-60 years, and 10-20% of those aged \>70 years \[[@R3],[@R4]\]. Both smoking and diabetes are risk factors for CAD and PAD, but these risk factors have a greater role in PAD than in CAD \[[@R5]\], suggesting that the frequency of PAD is likely to increase in the western world.

As atherosclerosis is a widespread disease of arteries, PAD is frequently associated with CAD \[[@R6]-[@R8]\]. Therefore, therapies such as statins, angiotensin-converting-enzyme inhibitors and antiplatelet drugs have been used for systemic treatment. However, at present, none of these agents can improve perfusion to the lower extremity in patients with PAD \[[@R4],[@R9]\]. Revascularization by surgical bypass or catheter is the first option for PAD patients with stenosis or occlusion of large arteries, but many patients with critical limb ischemia (CLI) are poor candidates for these revascularization treatments because of the existence of diffuse stenosis or calcification of arteries. Moreover, re-stenosis of the treated artery or graft failure can arise as complications after successful revascularization \[[@R10],[@R11]\]. Clearly, the need exists to develop a new strategy for establishing biological grafts in PAD patients with no treatment option.

The concept of "therapeutic angiogenesis" for PAD, achieved by gene and cell therapy, has recently raised a great deal of hope for patients who cannot undergo standard revascularization treatment. Cell therapy using bone marrow stem cells is still at a primitive stage, but holds great hope \[[@R12]\]. On the other hand, gene therapy for PAD patients has been intensively validated by large randomized, multi-center, double-blinded, placebo-controlled trials. Although preclinical studies using vascular endothelial growth factor (VEGF) \[[@R13]\] and fibroblast growth factor (FGF) \[[@R14]\] gave very promising data, the enthusiasm generated by these early studies has been let down by the results from large randomized, multi-center, double-blinded, placebo-controlled trials \[[@R15],[@R16]\]. Recently, a multicenter, double-blind, placebo-controlled phase III clinical trial in Japan and a US phase II clinical trial of hepatocyte growth factor (HGF) gene therapy for CLI demonstrated a significant improvement in primary end points and an increase in transcutaneous partial oxygen pressure even after one year in comparison to placebo \[[@R17],[@R18]\]. These results indicate that there might be a distinct beneficial function of HGF among angiogenic growth factors in a clinical setting.

This review provides an overview of the outcomes of clinical trials of gene therapy for PAD patients. A potential explanation for the success or fail of clinical trials is discussed later in the context of the biological mechanisms underlying angiogenesis and vascular remodeling, including cellular senescence, inflammation, and tissue fibrosis in pathological condition.

PROCESS OF VESSEL FORMATION AND REMODELING
==========================================

Acute arterial occlusion in the lower extremity, *i.e.* a blood clot, embolism, dissection or trauma, usually causes severe tissue ischemia, resulting in tissue necrosis necessitating limb amputation. Conversely, gradually developing arterial stenosis, *i.e.* atherosclerosis, stimulates the growth of pre-existing bypass circulation. This formation of collateral vessel, with 20-100 ìm diameter and fully developed tunica media that allow vasodilatation and regulation of blood flow, is called 'arteriogenesis'. These vessels can grow considerably, enough to take over the role of a large artery when occluded. Arteriogenesis is independent of oxygen levels and ischemia. Instead, it is enhanced by the change in shear stress forces sensed by endothelial cells through NO production. Tissue ischemia also leads to the sprouting of new capillaries from pre-existing vessels, termed 'angiogenesis'. These 8-12 µm diameter vessels lie within the ischemic region, connecting to the capillaries derived from normally perfused arterioles. As this process leads predominantly to the development of small capillaries, angiogenesis is unable to fully compensate for the occlusion of larger arteries \[[@R1],[@R19]\]. In contrast to arteriogenesis, angiogenesis is stimulated by ischemia and hypoxia signaling. Another type of vessel formation termed 'vasculogenesis' is defined as the in situ formation of blood vessels. It was thought that vasculogenesis was limited to embryonic development. However, in 1997, Asahara *et al.* demonstrated that circulating endothelial progenitor cells (EPC) can be incorporated into newly formed vessels following limb ischemia \[[@R20]\]. EPC can be involved in the processes of both arteriogenesis and angiogenesis by secreting cytokines or forming new endothelial cells. Although their actual role in physiological condition in adulthood remains largely unknown, interestingly, BM-derived EPC could be detected even in the wall of quiescent vessels without neovascularization events. This finding suggests that BM-derived EPC may relate even to the turnover of EC in quiescent vessels \[[@R21]\].

ANGIOGENIC GROWTH FACTORS AND CLINICAL OUTCOMES
===============================================

Angiogenic growth factors have the ability to increase collateral vessels, and augment tissue perfusion and oxygenation, limiting ischemic lesions in rodents \[[@R22],[@R23]\]. Therefore, they have been expected to improve the function and symptoms of patients with CLI. Initially, interest in utilizing angiogenic cytokines for clinical intervention focused on VEGF and FGF. Later, the therapeutic potential of HGF has been identified (Table **[1](#T1){ref-type="table"}**).

VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
=========================================

VEGF has been widely and intensively studied for its angiogenic potential in both cancer and tissue ischemia \[[@R24],[@R25]\]. The VEGF family consists of VEGF-A to E. VEGF-A and B have alternative splicing variant isoforms (*e.g.*, VEGFA~121~, VEGF~165~). Among VEGF-A isoforms, VEGF~165~ is the most abundant, and the best characterized \[[@R26]\]. Experimentally, plasmid- and adenovirus vector-mediated VEGF over-expression significantly ameliorated tissue perfusion and oxygenation with neovascularization in a hind-limb ischemia model \[[@R27],[@R28]\]. VEGF over-expression results in proliferation of resident endothelial cells (EC) and endothelial progenitor cell (EPC) recruitment, with subsequent neovascularization \[[@R29],[@R30]\]. Clinically, VEGF gene therapy provides inconsistent findings. Phase I clinical trials demonstrated that naked-plasmid VEGF~165~ gene therapy is safe and feasible, and over-expression of the cytokine in skeletal muscle significantly improved tissue perfusion and wound healing \[[@R13]\]. Consistently, Makinen *et al.* showed that intra-arterial administration of Ad-VEGF~165~markedly increased vascular density compared to the placebo-control group \[[@R31]\]. Contrary to VEGF~165~ administration, intramuscular injection of the Ad-VEGF~121~ isoform failed to show an improvement in claudication, ankle-brachial index, and quality of life in a phase II clinical trial \[[@R32]\]. Moreover, up to this time, no phase III clinical trial using VEGF gene transfer has shown an improvement. It has long been documented that VEGF therapy was strongly associated with dose-dependent microvascular permeability and peripheral edema; 60% of patients developed moderate or severe edema in a clinical trial. VEGF-induced vascular permeability is caused by Rac-mediated generation of ROS, which, in turn, regulates adherens junction integrity \[[@R33]\]. However, a recent publication by Ehrbar *et al.* demonstrated that controlling the level of VEGF in mouse model with unique delivery systems (α2PI~1-8~-VEGF~121~) generated non-leaky vessels and ameliorated vessel formation more potently than did native VEGF~121~\[[@R34]\]~.~Slow-release, low-dose VEGF might be effective and feasible in clinical trials.

FIBROBLAST GROWTH FACTOR (FGF)
==============================

The FGF family consists of approximately 22 members that bind to various spliced isoforms of the FGF receptors. Activation of the FGF receptors, which are expressed on EC, smooth muscle cells (SMC), and EPC, stimulates the proliferation of the respective cell types \[[@R35]\]. In particular, FGF-1 (acidic), FGF-2 (basic), and FGF-4 are highly angiogenic, and have the ability to enhance blood-vessel formation to facilitate angiogenesis with sprouting of capillaries from vessels. Based on these experimental data, a naked DNA plasmid vector (non-viral FGF vector; NV1FGF) carrying human FGF-1 has been developed for gene therapy. Pre-clinical studies demonstrated its potential to generate a functional vascular network in the ischemic region \[[@R36]\]. A phase I clinical trial enrolling 51 patients demonstrated a significant improvement in ulcer size, claudication, ankle brachial index, and transcutaneous tissue oxygen in the ischemic limb \[[@R14]\]. The subsequent phase II clinical trial (TALISMAN) also showed promising results, with improvement of ulcer healing and decreased risk of amputation or death \[[@R37]\]. With great hope, a phase III randomized clinical trial (TAMARIS) was conducted in patients who were not eligible for revascularization \[[@R16]\], but unexpectedly, no benefit of NV1FGF was detected in either the primary efficacy endpoint (major amputation or death) or secondary endpoints (minor amputation, skin lesion status, pain index, quality of life, and ankle and toe brachial index). It has been reported that FGF gene therapy is associated with potential hypertension and membranous nephropathy; these adverse effects have to be carefully considered in determining the dose and duration of administration of FGF.

HEPATOCYTE GROWTH FACTOR (HGF)
==============================

HGF was initially discovered as a potent mitogen for hepatocytes \[[@R38]\]. Later, its angiogenic potential; EC proliferation and migration, *via* tyrosine phosphorylation of its receptor, c-Met, was discovered. The receptor c-Met is expressed on EC, SMC, and also EPC \[[@R39]\]. Data obtained from clinical trials using the HGF gene for the treatment of hind-limb ischemia are particularly appealing, because at least three randomized placebo-controlled clinical trials using naked human HGF plasmid DNA verified its beneficial effect in healing of ulcers, decrease in rest pain, and increase in transcutaneus oxygen tension \[[@R17],[@R18],[@R40]\]. Recently, our group demonstrated long-term efficacy of HGF gene therapy with an increase in ankle-brachial pressure index, and a reduction of rest pain and ulcer size two years after gene therapy \[[@R41]\]. It is also worth mentioning that, unlike VEGF, HGF gene therapy was not associated with edema as a side effect.

These clinical results obtained from VEGF, FGF, and HGF gene therapy for PAD patients made us think about the distinct molecular mechanism of HGF and the difference between animal experiments and clinical trials which might provide a cue to improve therapeutic angiogenesis with growth factors.

WHAT IS SUCCESSFUL THERAPEUTIC ANGIOGENESIS?
============================================

The goal of therapeutic angiogenesis using gene therapy for CLI patients is to provide relief from ischemic pain, heal ulcers, reduce amputation risk, and afford a better quality of life. The advanced disease pathology features characteristically observed in the elderly introduces several obstacles, including severe inflammation, atherosclerosis, and ischemia, which all confound the efficacy of therapeutic angiogenesis by gene therapy for revascularization. At the cellular level, these undesirable features of CLI cause cell apoptosis, senescence, and fibrosis.

Cellular Apoptosis
------------------

Capillary density in human leg skeletal muscle varies only slightly between persons \[[@R42]\]. However, it can be increased by exercise and decreased by age, hypertension, or reduction in muscle use. CLI and PAD are typical age-associated disease, and patients with intermittent claudication have decreased exercise tolerance due to exercise-induced muscle ischemia. Moreover, hypertension, hypercholesterolemia, current smoking, and low kidney function were positively associated with prevalent PAD. More than 95% of persons with PAD had one or more cardiovascular disease risk factors \[[@R43]\]. These findings are due to the fact that PAD is associated with lower capillary density, and capillary density is related to the functional impairment as defined by a reduced peak oxygen consumption and peak walking time \[[@R44]\].

Cellular Senescence
-------------------

It is also noteworthy that capillaries in PAD patients may have a senescent phenotype due to vascular risk factors, inflammation, and aging. This hypothesis is supported by the fact that Angiotensin II-, TNF-α, and diabetes-induce premature senescence *in vivo* animal experiment and *in vitro* study \[[@R45]-[@R49]\]. Additionally, EPC senescence is associated with the cardiovascular risk factors.

Tissue Fibrosis
---------------

Another important factor that prevent tissue repair is fibrosis. Tissue fibrosis often presents as the final outcome of chronic disease and is a significant cause of morbidity and mortality worldwide. Fibrosis is driven by continuous expansion of fibroblasts and myofibroblasts. Epithelial-mesenchymal transition (EMT) is a form of cell plasticity in which epithelia acquire mesenchymal phenotypes, and is increasingly recognized as an integral aspect of tissue fibrogenesis. Tissue fibrosis prevents oxygen diffusion and resident stem/progenitor cell migration toward the region where tissue repair is required.

Thus, several complications in human that have not been well examined in pre-clinical studies need to be overcome for successful angiogenesis in clinical trials. The next paragraph discussed possible beneficial mechanism of HGF in comparison to VEGF and FGF.

POSSIBLE DIFFERENCE BETWEEN HGF AND OTHER GROWTH FACTORS
========================================================

HGF was initially discovered as a hepatotrophic factor present in the plasma of patients with fulminant hepatic failure \[[@R38]\]. Subsequently, several lines of evidence have implied that the HGF/c-Met system has several roles in different aspects of cellular biology including cell survival, cell differentiation and proliferation, and cytokine production \[[@R50]-[@R52]\]. Therefore, HGF is now appreciated as a key growth cytokine in the prevention and attenuation of both acute and chronic disease progression in the heart \[[@R53]\], kidney \[[@R50]\], liver \[[@R54]\], and vascular repair \[[@R46],[@R47]\]. Among HGF's beneficial functions, its anti-inflammatory and anti-fibrotic action differentiate HGF from VEGF and bFGF. Inflammation, characterized by infiltration of inflammatory response cells, has been thought to be essential in the initiation and progression of a wide range of chronic diseases, including heart, kidney, and lung diseases \[[@R55]-[@R57]\]. Importantly, inflammation has recently been shown to be associate with cellular senescence \[[@R58]-[@R60]\]. IL-6 and IL-8 have been shown to play a pivotal role in the initiation and maintenance of cellular senescence. Reactive oxygen species (ROS) induced by inflammation also cause cellular senescence \[[@R61]\]. Thus, relation between inflammation and cellular senescence is evident. Nonetheless, most of the preclinical studies, including hind-limb ischemia model and acute myocardial infarction model, have been performed in the absence of vascular risk factor, which are present in a clinical setting.

To elucidate the discrepancy between the HGF and VEGF clinical trial outcomes, we compared the effects of HGF and VEGF on EC and EPC under angiotensin II (Ang II) stimulation, which is secreted by inflammatory cells and promotes atherosclerosis. We found that HGF, but not VEGF, attenuated Ang II-induced senescence of EC and EPC through a reduction of oxidative stress by inhibition of the PIP3/rac1 pathway \[[@R46]\]. Potent induction of neovascularization through recruitment of EPC by HGF under Ang II was also confirmed by *in vivo* experiments using several models, including HGF transgenic mice. However, this action was not seen with VEGF. Surprisingly, HGF and its receptor, c-Met, down-regulate epithelial growth factor receptor (EGFR) in ligand-dependent manner through the ubiquitin proteasome system \[[@R47]\]. Moreover, HGF down-regulates EGFR expression following administration of lipopolysaccharide (LPS), endothelin-1 (ET-1), and transforming growth factor alpha (TGF-a), which transactivate EGFR, suggesting that ligand-dependent EGFR down-regulation of HGF might be the major anti-inflammatory and anti-oxidant mechanism of HGF \[[@R47],[@R62]\]. Also, Kaga *et al.* demonstrated that bFGF alone, but not HGF, significantly activated a fundamental transcription factor for inflammation, NFκB, and gene expression of its downstream inflammation-associated cytokines (IL-8 and MCP-1) in VSMC, accompanied by an increase in vascular permeability in a rat paper disc model \[[@R63]\]. Also, Ohtani *et al.* proved that expression of VEGF increases after neointimal injury, recruiting monocyte-lineage cells \[[@R64]\]. Importantly, HGF was shown to have a synergistic action with VEGF on EC proliferation and chemotactic response and neovascularization \[[@R65],[@R66]\]. The authors also revealed that HGF up-regulated VEGF mRNA transcript, while HGF gene therapy did not induce leaky vessels or edema. Min *et al.* reported that HGF markedly reduced VEGF-induced leukocyte adhesion and adhesion molecule expression. This effect was mediated by HGF suppression of VEGF-induced NFκB signaling \[[@R67]\]. Thus, HGF stimulates new vessel growth accompanied by inhibition of complication of inflammation, edema, and cellular senescence.

A further unique function of HGF is its anti-fibrotic action, while VEGF and FGF were shown to induce tissue fibrosis \[[@R68],[@R69]\]. We demonstrated that up-regulation of HGF resulted in a significant decrease in fibrotic tissue following acute myocardial infarction \[[@R52]\]. Moreover, our recent work demonstrated that HGF significantly attenuates endothelial-mesenchymal transition, which is considered to be involved in perivascular fibrosis in the heart \[[@R70]\] and kidney \[[@R50]\]. These actions would serve to minimize obstacles to tissue regeneration. Intramuscular fibrosis might prevent resident stem/progenitor cell migration. In the same way, perivascular fibrosis would limit engraftment of circulating stem/progenitor cells and oxygen diffusion, leading to im-pairment of tissue regeneration and oxygenation. Since local HGF expression was decreased in the muscle of an ischemic hind-limb model, where vascular and intramuscular fibrosis cause disease progression \[[@R71]\], administration of HGF by gene therapy would be expected to have a significant influence on neovascularization and regeneration of the organ. In fact, HGF stimulates resident cardiac stem cell improving cardiac function in the infarct mice heart where fibrosis complicates pathological condition \[[@R72]\]. Thus, these different properties of HGF, VEGF, and bFGF might affect the efficiency of therapeutic angiogenesis (Fig. **[1](#F1){ref-type="fig"}**).

Although, differences in the dose and duration of gene therapy, vector selection, and endpoint selection should be considered in the interpretation of the results of clinical trials, we have to take into account limitations of preclinical studies and the complexities of clinical settings.

CONCLUSION
==========

Despite significant advances in medical, interventional, and surgical therapy, peripheral arterial disease patients are increasing with the aging world population \[[@R73]\]. To address this unmet need, scientists have accumulated data of therapeutic angiogenesis by gene therapy for more than ten years from clinical and preclinical studies. Unfortunately, we now recognize that the dramatic efficacy of single-angiogenic growth factor gene therapy that was shown in several animal studies was not fully translated into clinical practice. Comprehensive understanding of the basic biology of neovascularization in pathological conditions would provide critical information for future successful therapeutic angiogenesis. Although it is challenging to translate basic research to the clinical situations, HGF has unique potential and might be more ideal for the treatment of complex conditions in advanced peripheral artery disease patients.

LIMITATION OF CLINICAL DATA AND FUTURE PERSPECTIVES
===================================================

The optimal dose, duration and timing of gene therapy have yet to be determined. In preclinical non-ischemic animal model, it is suggested that angiogenesis might need to be induced for weeks or months before the newly formed vasculatures mature \[[@R74],[@R75]\]. However, it is unclear whether persistent angiogenic stimuli is required for the ischemia in clinical setting. Naked plasmid DNA is expressed for only few days, and likewise adenovirus gene expression is expected to sustain for few weeks. Thus, a more robust exploration of dose and duration strategies may need to be tested after safety data accumulates regarding these approaches. Delivery route and vector selection should also be optimized as well. Intramuscular gene administration is a simple procedure. New methodology such as ultrasound --mediated administration of plasmid DNA \[[@R76]\] and intravenous retrograde gene delivery \[[@R77]\] can be applied for CLI patient with main artery occlusion. The ideal vector would combine low immunogenicity and safety profile with high transfection efficiency and gene expression for certain period of time. These optimization will provide benefit for patients with CLI.

The number of patients with cardiovascular disease will increase dramatically, as the population of developed nation ages. Thus, angiogeninc gene therapy and other strategies including stem cell therapy are needed to lessen the burden of ischemic disease and to improve quality of life. The challenges in clinical and the lesson from preclinical studies might offer therapeutic development. We are currently establishing strategy to treat patient with heart failure by administration of HGF plasmid.
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###### 

Human Clinical Trials of Angiogenic Growth Factors for Patients with PAD

  **Trials (Reference)**        **Strategy**     **Phase**   **Outcome**
  ----------------------------- ---------------- ----------- -----------------------------------------------------
  Baumgartner *et al.* \[13\]   phVEGF~165~      I           Tolerated
  Makinen *et al.* \[31\]       phVEGF~165~      I           Tolerated
  RAVE \[32\]                   AdenoVEGF~121~   II          No improvement of exercise performance or QOL
  Groningen \[15\]              phVEGF~165~      II          No reduction in amputation rate
  Comerota *et al.* \[14\]      phFGF-1          I           Tolerated
  TALISMAN \[37\]               phFGF-1          II          Reduction in amputation rate
  TAMARIS \[16\]                phFGF-1          III         No reduction in amputation rate or death
                                                             No improvement of QOL or ABI
  Morishita *et al.* \[40\]     phHGF            I/IIa       Tolerated
  Makino *et al.* \[41\]        phHGF            I/IIa       Improvement of ABI
                                                             Reduction in rest pain and ulcer size up to 2 years
  HGF-STAT \[17\]               phHGF            II          Improvement in TcPO~2~
  TREAT-HGF \[18\]              phHGF            III         Improvement in rest pain and ABI
                                                             Reduction in ulcer size

ABI: ankle-brachial index

TBI: toe-brachial index

TcPO2: transcutaneous oxygen tension
